 Sialic Acid Binding Ig-like Lectin 3
"Sialic Acid Binding Ig-like Lectin 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 67-kDa sialic acid binding lectin that is specific for MYELOID CELLS and MONOCYTE-MACROPHAGE PRECURSOR CELLS. This protein is the smallest siglec subtype and contains a single immunoglobulin C2-set domain. It may play a role in intracellular signaling via its interaction with SHP-1 PROTEIN-TYROSINE PHOSPHATASE and SHP-2 PROTEIN-TYROSINE PHOSPHATASE.
| Descriptor ID |
D063268
|
| MeSH Number(s) |
D12.776.503.921.400 D23.050.301.264.035.913.300 D23.050.301.264.900.565 D23.101.100.110.929.300 D23.101.100.900.565
|
| Concept/Terms |
Sialic Acid Binding Ig-like Lectin 3- Sialic Acid Binding Ig-like Lectin 3
- Sialic Acid Binding Ig like Lectin 3
- CD33 Antigen
- Antigen, CD33
- Glycoprotein gp67
- gp67, Glycoprotein
- Siglec-3
- Antigens, CD33
- CD33 Antigens
|
Below are MeSH descriptors whose meaning is more general than "Sialic Acid Binding Ig-like Lectin 3".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Lectins [D12.776.503]
- Sialic Acid Binding Immunoglobulin-like Lectins [D12.776.503.921]
- Sialic Acid Binding Ig-like Lectin 3 [D12.776.503.921.400]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, CD [D23.050.301.264.035]
- Sialic Acid Binding Immunoglobulin-like Lectins [D23.050.301.264.035.913]
- Sialic Acid Binding Ig-like Lectin 3 [D23.050.301.264.035.913.300]
- Antigens, Differentiation, Myelomonocytic [D23.050.301.264.900]
- Sialic Acid Binding Ig-like Lectin 3 [D23.050.301.264.900.565]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, CD [D23.101.100.110]
- Sialic Acid Binding Immunoglobulin-like Lectins [D23.101.100.110.929]
- Sialic Acid Binding Ig-like Lectin 3 [D23.101.100.110.929.300]
- Antigens, Differentiation, Myelomonocytic [D23.101.100.900]
- Sialic Acid Binding Ig-like Lectin 3 [D23.101.100.900.565]
Below are MeSH descriptors whose meaning is more specific than "Sialic Acid Binding Ig-like Lectin 3".
This graph shows the total number of publications written about "Sialic Acid Binding Ig-like Lectin 3" by people in this website by year, and whether "Sialic Acid Binding Ig-like Lectin 3" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 0 | 1 | 1 | | 2013 | 1 | 0 | 1 | | 2016 | 1 | 0 | 1 | | 2017 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Sialic Acid Binding Ig-like Lectin 3" by people in Profiles.
-
Gbadamosi MO, Shastri VM, Elsayed AH, Ries R, Olabige O, Nguyen NHK, De Jesus A, Wang YC, Dang A, Hirsch BA, Alonzo TA, Gamis A, Meshinchi S, Lamba JK. A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials. Leukemia. 2022 08; 36(8):2022-2031.
-
Lamba JK, Voigt AP, Chauhan L, Shin M, Aplenc R, Eidenschink Brodersen L, Gamis AS, Meshinchi S, Loken MR. CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients. Leuk Lymphoma. 2018 09; 59(9):2250-2253.
-
Lamba JK, Chauhan L, Shin M, Loken MR, Pollard JA, Wang YC, Ries RE, Aplenc R, Hirsch BA, Raimondi SC, Walter RB, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S. CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531. J Clin Oncol. 2017 Aug 10; 35(23):2674-2682.
-
Pollard JA, Loken M, Gerbing RB, Raimondi SC, Hirsch BA, Aplenc R, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S. CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. J Clin Oncol. 2016 Mar 01; 34(7):747-55.
-
Mortland L, Alonzo TA, Walter RB, Gerbing RB, Mitra AK, Pollard JA, Loken MR, Hirsch B, Raimondi S, Franklin J, Pounds S, Cao X, Rubnitz JE, Ribeiro RC, Gamis A, Meshinchi S, Lamba JK. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy. Clin Cancer Res. 2013 Mar 15; 19(6):1620-7.
-
Pollard JA, Alonzo TA, Loken M, Gerbing RB, Ho PA, Bernstein ID, Raimondi SC, Hirsch B, Franklin J, Walter RB, Gamis A, Meshinchi S. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood. 2012 Apr 19; 119(16):3705-11.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|